Ptc Therapeutics (PTCT) Liabilities and Shareholders Equity (2016 - 2025)
Ptc Therapeutics (PTCT) has 14 years of Liabilities and Shareholders Equity data on record, last reported at $2.9 billion in Q4 2025.
- For Q4 2025, Liabilities and Shareholders Equity rose 70.01% year-over-year to $2.9 billion; the TTM value through Dec 2025 reached $10.8 billion, up 49.34%, while the annual FY2025 figure was $2.9 billion, 70.01% up from the prior year.
- Liabilities and Shareholders Equity reached $2.9 billion in Q4 2025 per PTCT's latest filing, up from $2.6 billion in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $2.9 billion in Q4 2025 and bottomed at $1.3 billion in Q3 2023.
- Average Liabilities and Shareholders Equity over 5 years is $2.0 billion, with a median of $1.9 billion recorded in 2023.
- Peak YoY movement for Liabilities and Shareholders Equity: fell 25.83% in 2023, then skyrocketed 70.01% in 2025.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.9 billion in 2021, then fell by 11.99% to $1.7 billion in 2022, then increased by 11.14% to $1.9 billion in 2023, then decreased by 10.06% to $1.7 billion in 2024, then surged by 70.01% to $2.9 billion in 2025.
- Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $2.9 billion in Q4 2025, $2.6 billion in Q3 2025, and $2.6 billion in Q2 2025.